-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Hehuang Pharmaceutical (00013.HK) announced that the phase III registration phase of the ESLIM-02 study on the novel spleen tyrosine kinase (Syk) inhibitor zolepinib for the treatment of adult patients with warm-antibody autoimmune hemolytic anemia has reached the main end point of persistent hemoglobin (Hb) response during 5 to 24 weeks of treatment.

Zhitongcaijing·01/07/2026 00:09:02
Listen to the news
Zhitong Finance App News, Hehuang Pharmaceutical (00013.HK) announced that the phase III registration phase of the ESLIM-02 study on the novel spleen tyrosine kinase (Syk) inhibitor zolepinib for the treatment of adult patients with warm-antibody autoimmune hemolytic anemia has reached the main end point of persistent hemoglobin (Hb) response during 5 to 24 weeks of treatment.